Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1129-2377
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence ; volume:21 ; number:1 ; day:3 ; month:7 ; year:2020 ; pages:1-5 ; date:12.2020
The journal of headache and pain ; 21, Heft 1 (3.7.2020), 1-5, 12.2020

Urheber
Scheffler, Armin
Messel, Olga
Wurthmann, Sebastian
Nsaka, Michael
Kleinschnitz, Christoph
Glas, Martin
Naegel, Steffen
Holle, Dagny
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s10194-020-01151-0
URN
urn:nbn:de:101:1-2020083119175561194493
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:03 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Scheffler, Armin
  • Messel, Olga
  • Wurthmann, Sebastian
  • Nsaka, Michael
  • Kleinschnitz, Christoph
  • Glas, Martin
  • Naegel, Steffen
  • Holle, Dagny
  • SpringerLink (Online service)

Ähnliche Objekte (12)

A prospective real-world analysis of erenumab in refractory chronic migraine

A prospective real-world analysis of erenumab in refractory chronic migraine

Combined Interventional Treatment of Refractory Chronic Migraine

Combined Interventional Treatment of Refractory Chronic Migraine

Refractory migraine in a headache clinic population

Refractory migraine in a headache clinic population

Identifying and managing refractory migraine: barriers and opportunities?

Identifying and managing refractory migraine: barriers and opportunities?

First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration

First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration

Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine

Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series

Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

Verbundene Objekte